Recent Updates
Recently added Catalysts
MCK Positive Sentiment

McKesson Signs Agreement to Acquire Precision Medicine Group, LLC

Key Takeaway: McKesson Corporation has signed a definitive agreement to acquire Precision Medicine Group for approximately $2.25 billion. This acquisition aims to enhance McKesson's offerings in clinical research and biopharma commercialization. Post-transaction, Precision Medicine Group will be integrated into McKesson's Oncology & Multispecialty segment.

Market Sentiment Analysis

POSITIVE FACTORS

  • McKesson is expanding its capabilities in clinical research.
  • The acquisition enhances McKesson's oncology and multispecialty services.
  • Precision Medicine Group is a reputable provider in biopharma commercialization.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~71 mo
Minimal dilution risk
Lead asset
Pegylated liposomal doxorubicin
Phase 2 · Metastatic Breast Cancer

Full Press Release Details

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (“Precision Medicine Group”), a global provider of clinical research and biopharma commercialization services. McKesson will acquire Precision Medicine Group for approximately $2.25 billion. Following completion of the transaction, Precision Medicine Group will report within McKesson’s Oncology & Multispecialty segment. The transacti

Frequently Asked Questions

What is the value of McKesson's acquisition?

McKesson's acquisition of Precision Medicine Group is valued at approximately $2.25 billion.

What services does Precision Medicine Group provide?

Precision Medicine Group is a global provider of clinical research and biopharma commercialization services.

In which segment will Precision Medicine Group report?

After the acquisition, Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment.

Last updated: Aug 25, 2026